Genetics and epigenetics of arrhythmia and heart failure

Burcu Duygu, Ella M. Poels and Paula A. da Costa Martins*

Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands

INTRODUCTION
Genetic mutations can contribute to the diverse pathologies of heart failure (HF) by altering structure and therefore, the function of proteins responsible for various cellular activities (Cooremans et al., 2011). While several studies have been devoted to the evaluation of genetic factors related to heart disease and genetic complications, much less is known about the relevance of epigenetics. The term “epigenetics” is defined as changes in gene expression that cannot be explained by changes in DNA sequence (Egger et al., 2004) but rather result from alterations related to packaging and/or translation of genetic information (Bird, 2007). Epigenetic mechanisms can be acquired or heritable and constitute a mean by which interactions between genes and environment can occur. Epigenetic regulation occurs by three key mechanisms: (i) methylation of CpG islands, mediated by DNA methyltransferases (DNMTs), (ii) modification of histone proteins and (iii) microRNAs (miRNAs). Such modifications will lead to differential expression of similar information depending on the surrounding conditions, resulting in gene activation or silencing. Although epigenetic variability of genetic information is part of normal development and differentiation, it also depends on exogenous stimuli (e.g., smoking, drug abuse) and can, therefore, reflect the influence of those factors on the development of disease (Feinberg, 2007). The role of epigenetics has been mainly evaluated in cancer but recent studies have begun to address the involvement of epigenetics in the development and progression of cardiovascular diseases (CVD).

Heart failure (HF) is the end stage of several pathological cardiac conditions including myocardial infarction, cardiac hypertrophy and hypertension. Various molecular and cellular mechanisms are involved in the development of HF. At the molecular level, the onset of HF is associated with reprogramming of gene expression, including downregulation of the alpha-myosin heavy chain (α-MHC) gene and sarcoplasmic reticulum Ca2+ ATPase genes and reactivation of specific fetal cardiac genes such as atrial natriuretic factor and brain natriuretic peptide. These deviations in gene expression result in structural and electrophysiological changes, which eventually progress to HF. Cardiac arrhythmia is caused by altered conduction properties of the heart, which may arise in response to ischemia, inflammation, fibrosis, aging or from genetic factors. Because changes in the gene transcription program may have crucial consequences as deteriorated cardiac function, understanding the molecular mechanisms involved in the process has become a priority in the field. In this context, various studies besides having identified different DNA methylation patterns in HF patients, have also focused on specific disease processes and their underlying mechanisms, also introducing new concepts such as epigenomics. This review highlights specific genetic mutations associated with the onset and progression of HF, also providing an introduction to epigenetic mechanisms such as histone modifications, DNA methylation and RNA-based modification, and highlights the relation between epigenetics, arrhythmogenesis and HF.

Keywords: arrhythmia, heart failure, genetic predisposition to disease, epigenetic regulation, microRNAs, pharmacogenomics

www.frontiernet.org October 2013 | Volume 4 | Article 219 | 1

“fgene-04-00219” — 2013/10/30 — 11:38 — page 1 — #1
and highlights the relation between epigenetics, arrhythmogenesis and HF.

**GENETICS OF HEART FAILURE**

Genetic forms of HF are mainly known as familial dilated cardiomyopathy (FDCM). There are, however, two other familial forms of cardiomyopathy: hypertrophic cardiomyopathy (HCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC). In fact, FHCM is the most common form of inherited HF with a prevalence of 1 in every 500 individuals (Rodriguez et al., 2009). FDCM is mainly defined as unexplained left ventricular hypertrophy with increased heart mass (Elliott and McKenna, 2004). The majority of patients with FHCM (approximately 60%) exhibit autosomal dominant mutations in genes encoding for sarcomere proteins such as β-myosin heavy chain (MYH7), cardiac myosin binding protein C (MYBPC3), cardiac troponin I (TNNI2), troponin I (TNNI3), alpha-tropomyosin (TPM1), myosin light chains (MYL2 and MYL3) and cardiac actin (ACTC1; Morita et al., 2008, 2010; Lopes and Elliott, 2013).

Familial dilated cardiomyopathy is characterized as idiopathic DCM with a prevalence of 20–50% determined by epidemiological studies using family history and clinical, electrocardiographic and echocardiographic screening of first-degree relatives (Michels et al., 1992; Grunig et al., 1998). FDCM is mainly inherited in an autosomal dominant manner (approximately 90%) however, X-linked (5–10%) and much less commonly autosomal recessive (AR) or mitochondrial inheritance have also been reported (Hershberger et al., 2009). A genetic cause of FDCM was identified in 30–35% cases and mainly variant mutations of Lamin A/C (LMNA) have been reported as the most common cause of FHCM (in 7.3% of patients with DCM; Hershberger et al., 2009; Hershberger and Siegfried, 2011). In a recent study, Titin (TTN) truncating mutations were attributed as the cause of FDCM in 27% of a total of 312 DCM patients (Herman et al., 2012). Furthermore, GATA zinc finger domain containing protein 1 (GATA1) has been identified as a disease-causing gene for AR DCM by genome-wide mapping and exome sequencing in a unique family (Theis et al., 2011).

**EPIGENETIC MECHANISMS**

There are several epigenetic mechanisms in eukaryotes and many have already been linked to cardiac development, CVD and/or HF. The main alterations encompassing epigenetics in CVD are described below and include ATP-dependent chromatin remodelers. In fact, chromatin modification through ATP-dependent enzymes is associated with regulation of expression of transcription factors. Consequently, these unique domains and their associated proteins determine the genomic targeting specificity and biological functions of each family of chromatin remodelers. In fact, chromatin modification through ATP-dependent enzymes is associated with regulation of expression of distinct gene programs in organ development and adaptation (Ho and Crabtree, 2010).

**DNA METHYLATION**

DNA methylation is the most common epigenetic modification in the mammalian genome. This long-term stable epigenetic modification involves the addition of a methyl group to the 5′ carbon of a cytosine by DNMT enzymes (Figure 1) and mostly occurs at the CpG (cytosine preceding guanosine) dinucleotide sequences, also known as CpG islands, in the mammalian genome (Feinberg, 2008). CpG islands, in contrast to the remainder genome, are cytosine-guanosine-rich sequences (CpG-rich), generally not methylated (Deaton and Bird, 2011), and mostly acting as sites of transcription initiation once they are associated with promoter regions of genes (~70% of gene promoters; Li et al., 1995; Saunov et al., 2006). DNA methylation is known to be catalyzed by three different DNMTs: DNMT1, DNMT3a and DNMT3b (Broadbent et al., 2008), where DNMT1 is the core enzyme in mammals. Methylation of DNA is considered a maintenance function of DNMTs as it results in post-replicative restoration of hemi-methylated sites to full methylation (Laird, 2003). Reduction of DNMT1 activity may result in demethylation and recent studies even showed that this is an active process (Blutani et al., 2011). However this has not been shown yet for the cardiovascular system.

DNA methylation is, generally, attributed to gene silencing by hampering the accessibility of cis-DNA binding elements present in the promoter regions of genes of the transcriptional machinery (Saeki and Bird, 2008) and plays a crucial role in the regulation of chromatin structure including X chromosome inactivation, genomic imprinting, silencing of repetitive DNA elements and transposon transcription (Li et al., 1993; Panning and Jaenisch, 1996; Li, 2002). Moreover, DNA methylation has been linked to biological processes underlying various diseases from cancer (Feinberg and Tycko, 2004) to CVD, such as hypertension (Mills, 2011), diabetes (Ling and Groop, 2009; MacFarlane et al., 2009), atherosclerosis and inflammation (Wierda et al., 2010).

**HISTONE MODIFICATIONS**

The eukaryotic DNA is tightly compact and organized in chromatin. The nucleosome is the central unit of chromatin and is composed of an octamer center of two copies of each histone protein (H2A, H2B, H3, and H4; Jenuwein and Allis, 2001) around which a DNA segment of 14–150 base pairs is looped.
Each histone has an amino-terminal tail that protrudes from the surface of the nucleosome and which can be subjected to various posttranscriptional modifications such as phosphorylation, sumoylation, ubiquitination, methylation, ADP-ribosylation, proline isomerization, deimination and acetylation (Handy et al., 2011). These modifications lead to conformational changes in the chromatin resulting in altered gene expression (Margueron and Reinberg, 2010) depending on whether DNA becomes accessible (euchromatin) or inaccessible (heterochromatin) for transcription (Figure 1).

HISTONE ACETYLATION
Histone acetylation occurs at the lysine residues of the histone tails resulting in de-condensation of the chromatin structure and serving as a binding site for bromodomain proteins and transcriptional activators, and eventually leading to transcriptional activation (Ellis and McKenna, 2004; Rodriguez et al., 2009). Conversely, histone deacetylation induces chromatin condensation and therefore transcriptional repression (Clayton et al., 2006; Shahbazian and Grunstein, 2007; Figure 1). Acetylation of histones is a dynamic process mediated by two counteracting enzyme families, the histone acetyltransferases (HATs) and histone deacetylases (HDACs). The harmony between the activities of these two sets of enzymes is a crucial element during regulation of gene expression and its deregulation is linked to several pathological conditions varying from cancer to CVD (Oudovas and Smith, 2016; Burgess, 2012).

HISTONE METHYLATION
Other key modulator of posttranscriptional regulation is histone methylation which can occur on all basic amino acid residues of the histone tail; arginines, lysines and histidines (Cheung and Lau, 2005). In addition, different amino acids can be methylated to a different extent and while lysine can be subjected to mono-, di- and trimethylation, arginine residues can only become mono- or dimethylated (Cheung and Lau, 2005). Methylation of histones is a dynamic process mediated by histone methyltransferases (HMTs) and histone demethylases (HDMs; Teperino et al., 2010) and, unlike acetylation, histone methylation can induce either activation or repression of gene expression depending on the target sites and degree of methylation (Lachner and Jenuwein, 2002; Figure 1). In contrast to histone acetylation, histone methylation governed mainly by HMTs SUV39H1 and G9a (Martin and Zhang, 2005; Shi and Whetstine, 2007), has long been considered to be a permanent epigenetic mark (Jenuwein and Allis, 2001). However, the discovery of new players such as HDMs has shifted the paradigm and, in fact, several studies showed that histone methylation is tightly regulated in inflammatory and metabolic disorders (Saccani and Natoli, 2002; Villeneuve et al., 2006; Brasacchio et al., 2009).

RNA-BASED MECHANISMS
It is now proven and accepted that the majority of the genomic DNA is transcribed as non-coding RNAs and that
such RNA species play pivotal regulatory roles during development (Sayed and Abdellatif, 2011), in response to environmental adversity (Ferguson, 2013), and at the onset and progression of disease (Sayed and Abdellatif, 2011). In this context, many studies were directed at revealing the role of non-coding RNAs in physiological and pathological processes.

There are two main classes of non-coding RNAs: infrastructural (small nuclear and nucleolar RNAs, ribosomal RNAs) and regulatory RNAs (miRNAs, long non-coding RNAs, small interfering RNAs and Piwi-interacting RNAs). To date, only miRNAs have been associated with epigenetic regulatory mechanisms in HF: Epigenetic regulation through long non-coding RNAs have been extensively studied in cancer but have also been associated with cardiovascular disease, mainly in maintenance of vascular homeostasis (Bobb et al., 2004; Li et al., 2010).

MICRONAS:

MicroRNAs were first described in the nematode Caenorhabditis elegans, in the early 1990s (Lee et al., 1993). From then on, a multitude of miRNAs have been identified and investigated, and presently there are ∼1600 human miRNA sequences annotated at miRBase19 (Kozomara and Griffiths-Jones, 2011).

miRNAs are transcribed as primary transcripts (pri-miRNA) from intergenic, intronic or exonic regions in the genome, by RNA polymerase II. These pri-miRNAs fold into a hairpin shape with a five prime (5') capped (m7GpppG) and a polyadenylated tail which is subsequently cleaved by an enzyme complex composed of the RNase III endonuclease Drosha and the dsRNA binding protein Pasha (also known as DiGeorge critical region 8; DGCR8; Lee et al., 2003, 2004). The resulting shorter (70–100 nucleotide in length) hairpin-shaped precursor miRNA (pre-miRNA) is transported from the nucleus into the cytoplasm by Ran-GTP and exportin-5 (Kim, 2004). In the cytoplasm, pre-miRNAs are further processed by a RNase III enzyme, Dicer, into a short (20–25 nucleotides in length) transient double stranded RNA molecule. At this stage, the formed mature RNA molecule is included in a protein complex – the so-called RNA-induced silencing complex (RISC), while the passenger strand is degraded (Winter et al., 2009). The RISC-miRNA complex specifically targets miRNA sequences leading to negative regulation of protein synthesis or mRNA degradation (Winter et al., 2009). One miRNA can regulate a vast number of mRNAs simultaneously (Lewis et al., 2003) by predominantly acting through destabilization of target miRNAs and subsequently leading to reduced protein output (Gio et al., 2010). Therefore, decreased protein production can result from a combination of mRNA destabilization and translational inhibition. MiRNAs have been shown to be involved in different pathological processes such as cancer and CVD (Lujambio and Lowe, 2012; Quiet and Olson, 2013). While in cancer epigenetic mechanisms have been widely associated with silencing of miRNA-encoding genes and thus recognized to greatly influence the expression of genetic information, only recently the importance of such mechanisms have started to be addressed in CVD, and more specifically in HF.

EPIGENETICS AND ARRHYTHMIA

Recent technological advances in DNA sequencing have enabled epigenome mapping and provided unprecedented insight into the distribution, interplay, and potential novel functions of chromatin modification and associated proteins. Remarkably, when using such technologies in evaluating the heart rhythm prominence of selected gene networks including epigenetic modulators, not previously associated with arrhythmia, were identified as relevant under particular circumstances. A first evidence for epigenetic regulation of cardiac rhythm was raised from a study conducting microarrays on heart rhythm determinants (HRD) on tissue from mice exposed to either intermittent or chronic hypoxia and untreated wild type mice. A different environment (hypoxia) profoundly restructured the HRD web by changing the hierarchy of the composing genes and by identifying new role players. This was the case for the epigenetic modulators HDAC3, Me2b and Me2c (Iacobas et al., 2010).

CHROMATIN REMODELING AND ARRHYTHMIA

Postural tachycardia syndrome (POTS) has multiple symptoms, one of such being tachycardia. Dysfunction of the norepinephrine transporter (NET) gene has previously been implicated in POTS, with a reported coding mutation in the NET gene (SLC6A2; Bayles et al., 2012). Head-up tilt experiments in POTS patients and showed that the expression of norepinephrine transported is lower in POTS patients compared to healthy subjects. In the absence of altered SLC6A2 gene sequence or promoter methylation, the observed reduced expression of norepinephrine was directly correlated with chromatin modifications. Changes in expression were attributable to increased binding of the repressive methyl CpG-binding protein 2 (MeCP2) regulatory complex, in association with an altered histone modification composition at the promoter region of the SLC6A2 gene (Bayles et al., 2012).

DNA METHYLATION AND ARRHYTHMIA

The KCNQ1 gene is located on chromosome 11 in a region that contains a cluster of 6 genes that are expressed from either only the maternal or the paternal allele. In mice, the KCNQ1 over-lapping transcript (KCNQ1ot1) is transcribed from a promoter located in intron 10 of the KCNQ1 gene. This promoter region is a CpG island and undergoes methylation on the maternal chromosome, preventing transcription, and therefore allowing expression of the gene cluster. However, this promoter region is not methylated on the paternal chromosome allowing expression of the gene cluster (Manconi-D’Nardo et al., 2003). The maternal allele is transcribed in early embryogenesis with the paternal allele being progressively methylated and therefore only activated during late embryogenesis.

Variable imprinting of the KCNQ1 gene provides a possible explanation for the existence of long QT syndrome (LQTS) in the absence of a coding sequence mutation in KCNQ1. Paternal imprinting is probably relieved in cardiac tissue, meaning that during differentiation methylation of the paternal chromosome must occur to block production of the suppressive KCNQ1ot1 transcript. Mutations that disrupt the CpG island could prevent methylation and silence the paternal allele in the heart.
Histone deacetylases-1 and -2 have important functions in regulating cardiac gene expression and cardiomycyte differentiation. While myocardium-specific deletion of either HDAC-1 or HDAC-2 results in no apparent cardiac phenotype, specific deletion of both in the murine myocardium, results in death within 2 weeks after birth, due to cardiac arrhythmias and dilated cardiomyopathy (Montgomery et al., 2007). This is likely caused by upregulation of genes that encode for fetal calcium channels and skeletal muscle-specific contractile proteins, including hyperpolarization-activated non-selection cation current (If) and T-type Ca2+ current (ICa, T), both involved in calcium handling. Such genes are normally transcriptionally repressed by the RE1-silencing transcription factor (REST) through class I histone modifications, leading to reduced H3K4me expression levels and is sufficient to alter subsequent gene expression profiles. One of those H3K4me-regulated genes is the Kv channel-interacting protein 2 (Kcnip2), a regulator of cardiac repolarization current that is known to have functions in arrhythmogenesis. Regulation of Kcnip2 by hypomethylated histone H3 lysine 4 (H3K4me) methyltransferase complex, leads to increased H3K4me expression levels and is sufficient to alter subsequent gene expression profiles. One of those H3K4me-regulated genes is the Kv channel-interacting protein 2 (Kcnip2), a regulator of cardiac repolarization current that is known to have functions in arrhythmogenesis. Regulation of Kcnip2 by hypomethylated histone H3 lysine 4 (H3K4me) methyltransferase complex, leads to increased H3K4me expression levels and is sufficient to alter subsequent gene expression profiles. One of those H3K4me-regulated genes is the Kv channel-interacting protein 2 (Kcnip2), a regulator of cardiac repolarization current that is known to have functions in arrhythmogenesis. Regulation of Kcnip2 by hypomethylated histone H3 lysine 4 (H3K4me) methyltransferase complex, leads to increased H3K4me expression levels and is sufficient to alter subsequent gene expression profiles. One of those H3K4me-regulated genes is the Kv channel-interacting protein 2 (Kcnip2), a regulator of cardiac repolarization current that is known to have functions in arrhythmogenesis. Regulation of Kcnip2 by hypomethylated histone H3 lysine 4 (H3K4me) methyltransferase complex, leads to increased H3K4me expression levels and is sufficient to alter subsequent gene expression profiles. One of those H3K4me-regulated genes is the Kv channel-interacting protein 2 (Kcnip2), a regulator of cardiac repolarization current that is known to have functions in arrhythmogenesis. Regulation of Kcnip2 by hypomethylated histone H3 lysine 4 (H3K4me) methyltransferase complex, leads to increased H3K4me expression levels and is sufficient to alter subsequent gene expression profiles. One of those H3K4me-regulated genes is the Kv channel-interacting protein 2 (Kcnip2), a regulator of cardiac repolarization current that is known to have functions in arrhythmogenesis. Regulation of Kcnip2 by hypomethylated histone H3 lysine 4 (H3K4me) methyltransferase complex, leads to increased H3K4me expression levels and is sufficient to alter subsequent gene expression profiles. One of those H3K4me-regulated genes is the Kv channel-interacting protein 2 (Kcnip2), a regulator of cardiac repolarization current that is known to have functions in arrhythmogenesis. Regulation of Kcnip2 by hypomethylated histone H3 lysine 4 (H3K4me) methyltransferase complex, leads to increased H3K4me expression levels and is sufficient to alter subsequent gene expression profiles. One of those H3K4me-regulated genes is the Kv channel-interacting protein 2 (Kcnip2), a regulator of cardiac repolarization current that is known to have functions in arrhythmogenesis. Regulation of Kcnip2 by hypomethylated histone H3 lysine 4 (H3K4me) methyltransferase complex, leads to increased H3K4me expression levels and is sufficient to alter subsequent gene expression profiles. One of those H3K4me-regulated genes is the Kv channel-interacting protein 2 (Kcnip2), a regulator of cardiac repolarization current that is known to have functions in arrhythmogenesis. Regulation of Kcnip2 by hypomethylated histone H3 lysine 4 (H3K4me) methyltransferase complex, leads to increased H3K4me expression levels and is sufficient to alter subsequent gene expression profiles. One of those H3K4me-regulated genes is the Kv channel-interacting protein 2 (Kcnip2), a regulator of cardiac repolarization current that is known to have functions in arrhythmogenesis. Regulation of Kcnip2 by hypomethylated histone H3 lysine 4 (H3K4me) methyltransferase complex, leads to increased H3K4me expression levels and is sufficient to alter subsequent gene expression profiles. One of those H3K4me-regulated genes is the Kv channel-interacting protein 2 (Kcnip2), a regulator of cardiac repolarization current that is known to have functions in arrhythmogenesis. Regulation of Kcnip2 by hypomethylated histone H3 lysine 4 (H3K4me) methyltransferase complex, leads to increased H3K4me expression levels and is sufficient to alter subsequent gene expression profiles.
disease where degeneration of the conduction system occurs and increased CACNA1C (Cav 1.2) expression, a cardiac L-type Ca²⁺ channel gene, is observed (Kim, 2013). The involvement of miR-1 in electrophysiology was further confirmed by a targeted deletion of miR-1-2 by Zhao et al. (2007), which lead to a high rate of sudden death, caused by conduction blockade due to direct targeting of Kir6.2, a transcription factor that regulates cardiac repolarization. In rats, induction of MI by occlusion of the left anterior descending artery results in miR-1 upregulation and arrhythmia exacerbation but treating the animals with an antisense inhibitor could abrogate these effects. Furthermore, miR-1 also directly targets KCNJ2, which encodes for the calcium channel subunit Kir 2.1, providing a possible mechanism for increase of arrhythmias in MI (Yang et al., 2007). The role of miR-1 in arrhythmogenesis was further confirmed in humans where atrial cells from AF patients display a 86% decrease in miR-1 expression, a subsequent increased Kir 2.1 protein expression and an increase in Ikr density (Girmatsion et al., 2009; Kim, 2013). MiR-1 is also involved in cardiac electrical remodeling in viral myocarditis where it is upregulated, resulting in decreased Cx43, which is required for transfer of electric activation, and indicating that miR-1 plays a role in intercellular communication.

Another prominent miRNA in the regulation of cardiac conduction is miR-133. Matkovich et al. (2010) showed that an increase in miR-133a leads to prolonged QT intervals. This miRNA is highly and preferentially expressed in cardiac and skeletal muscle and is known to regulate cardiac ion channels such as Kv4-encoded Iκ₄, with concomitant decreased levels of Iκ₂. Furthermore, the catalytic and regulatory subunits of protein phosphatase 2A (PP2A) are decreased in cardiomyocytes in chronic HF and were shown to be targets of both miR-1 and miR-133. Because pharmacologic inhibition of PP2A leads to altered diastolic Ca²⁺ waves this indicates a role for these two miRNAs in calcium handling (Belyavsky et al., 2011; Kim, 2013).

Interestingly, a relation between nicotine abuse and cardiac arrhythmias has been suggested by several studies. Nicotine treatment of canine atrial fibroblasts, resulted in upregulation of transforming growth factor-beta 1 (TGF-β1) and TGF-β receptor type II levels (TGF-βR II), with concomitant decreased levels of miR-133 and miR-590, both directly targeting TGF-β1 and TGF-βR II. This effect was abolished by synthetic downregulation of both miRNAs (Shan et al., 2009; Kim, 2013). Apart from miR-1 and miR-133, there are several other miRNAs that have been associated with regulation of cardiac conduction to some extent. This is the case for miR-212 that seems to regulate inward rectifier K⁺ current density by targeting Kir 2.1 (Kim, 2013), and for miR-21 which is increased in the left atria of patients with AF and which abrogation leads to repression of atrial fibrosis and AF (Adam et al., 2012; Cardin et al., 2012; Kim, 2013). Furthermore, conditional overexpression of miR-17-92 in cardiac and smooth muscle tissue results in both dilated, HCM as well as in arrhythmias. An increase in atrial and ventricular ectopy, as well as increased susceptibility to arrhythmia was observed in homozygous and heterozygous animals. After programmed electrical stimulation all transgenic animals developed sustained and lethal ventricular tachycardia (VT) or ventricular fibrillation (VF) and these effects were mainly caused by dysregulation of two downstream targets of miR-17-92, the lipid phosphatase and tensin homolog PTEN and Cx43 (Danielson et al., 2013). Likewise, also miR-155 and miR-181 have been associated with cardiac conduction defects. Circulating levels of miR-155 are upregulated in patients with specific angiotensin receptor type I (AT1R) polymorphisms that have been shown to be associated with an increased risk of ventricular tachyarrhythmias and sudden death (Blanco et al., 2012). In turn, miR-181a seems to play a role in VT after MI (Li et al., 2009). Altogether, the data available regarding the relation between miRNAs and arrhythmias establish miRNAs as crucial players in regulating cardiac electrophysiology and electric potential conduction through an array of different mechanisms.

**EPIGENETIC CONTROL OF HEART FAILURE**

Recent genetic and biochemical studies indicate that epigenetic changes play a crucial role in the development of cardiac hypertrophy and HF with dysregulation in histone acetylation status being directly linked to impaired contraction of cardiac myocytes. In fact, it has been shown that there is a cardiac chamber – specific histone acetylation pattern suggesting that cardiac ventricular chambers are epigenetically distinct (Mathiyalagan et al., 2010).

**ATP-DEPENDENT ENZYMEs AND CHROMATIN REMODELING IN HF**

ATP-dependent chromatin remodeling complexes play crucial roles in vertebrates, mainly in organ development and adaptation. Most of them have been associated with heart development and only a few were implicated in heart disease. The BAF (brahma-associated factor) complex is the vertebrate homolog of the yeast SWI/SNF family of chromatin remodelers. In mammals, this complex contains 12 protein components from which an ATPase subunit encoded by either Brg1 (brahma) or Brg1 (brahma-related gene 1). These two subunits, although highly homologous, exhibit distinctive functions in vivo. While several studies have demonstrated that individual subunits of the BAF complex are essential during heart development (Lickert et al., 2004; Takeuchi et al., 2007; Takeuchi and Bruneau, 2009) and may be implicated in human congenital diseases (Kitagawa et al., 2003; Bajpai et al., 2010), Brg1 was recently involved in cardiac disease (Hang et al., 2010). In embryos, Brg1 promotes myocyte proliferation and it preserves fetal cardiac differentiation by interacting with HDACs and poly (ADP-ribose) polymerase (PARP) to repress α-MHC to β-MHC shift. Brg1 (also known as Smarca4) is not expressed in the adult heart but it is reactivated by stress conditions such as pressure overload. Once reactivated, Brg1 forms a complex with its embryonic partners (HDAC and PARP), to induce the pathological α-MHC to β-MHC shift. Adult myocardial gene deletion of Brg1 inhibited cardiac hypertrophic growth and reversed the MHC switch. Accordingly, Brg1 is activated in patients with HCM, correlating with disease severity and MHC changes (Hang et al., 2010). PPAR is a nuclear enzyme known to respond to DNA damage and facilitate repair. Besides DNA repair, PPAR-1 also modulates chromatin to control the transcription machinery in response to diverse stimuli. Such stimuli induce PPAR activation and PAR-dependent stripping of histones from chromatin, thereby favoring the opening of chromatin.
to allow transcriptional regulation (Tulin and Spradling, 2003; Kim et al., 2004). PARP is activated in cardiac hypertrophy and its activity is increased in murine and human failing hearts (Pillai et al., 2005b; Xiao et al., 2005). Deletion of PARP-1 in mice or pharmacological inhibition of PARP activity decreases cardiac hypertrophy induced by angiotensin II (Pillai et al., 2006) or pressure overload (Pillai et al., 2005a; Xiao et al., 2005), delays the progression from hypertensive cardiomyopathy to HF (Barriga et al., 2009), decreases cell death and HF after MI (Palfi et al., 2006) and diminishes myocardial ischemia/reperfusion injury (Staibo et al., 2002).

Although very preliminary, there seems to be a link, at the chromatin level, between fetal hearts and adult diseased hearts, and in the future, targeting the regulation of chromatin remodeling processes may become a promising approach to prevent or maybe even reverse pathological cardiac hypertrophic growth and HF.

**DNA METHYLATION IN HEART FAILURE**

Unlike in other diseases such as cancer, the role of DNA methylation in HF remains elusive. Movassagh et al. (2010) compared genome-wide methylation profiles of left ventricle tissue from HF patients and healthy controls by methylated DNA immunoprecipitation-chip (MeDIP-chip), in which immunoprecipitation of methylated DNA is followed by microarray hybridization and further validated by bisulfite sequencing. As a result, three differentially methylated angiogenesis–related loci have been identified and correlated to differential expression levels of the corresponding gene (Movassagh et al., 2010). Hyper-methylation of the 5′ regulatory region of platelet endothelial cell adhesion molecule 1 (PECAM-1) and hypo-methylation of the angiotrin-like protein 2 (AMOTL2) in failing hearts correlated with reduced expression of those genes, while hyper-methylation within the Rho GTPase activating protein 24 gene (ARHGAP24) is correlated with increased expression of ARHGAP24 in failing hearts (Movassagh et al., 2011a). A genome-wide DNA methylation map of human hearts and revealed a significant decrease in global promoter methylation of genes with increased expression in failing hearts (Movassagh et al., 2011a). The genome-wide methylation profile of patients with idiopathic dilated cardiomyopathy was recently generated (Haas et al., 2013). In an attempt to validate the methylation profiling of the 20 most differentially methylated genes, MassARRAY and Bisulfite sequencing were used in a large independent cohort (30 patients; Baccarelli and Bollati, 2009). Interestingly, 12 (out of 20) genes showed similar methylation patterns between the two independent studies. Such approach allowed the identification of two novel genes with differential methylation profiles between patient and control subjects, lymphocyte antigen 75 (Ly75) and adenosine A2A receptor (adora2a). Curiously, downregulation of those genes in zebrafish by using specific morpholino technology resulted in reduced ventricular contractility and HF (Haas et al., 2013). More recently, DNA methylation was found to be responsible for the hypermutability of distinct cardiac genes. This is the case for the cardiac isoform of the myosin binding protein C gene (Mybpc3) that has a significantly higher level of exonic methylation of CpG sites than the skeletal isoform (Mybpc2; Meurs and Kuan, 2011). This suggests that there are unique aspects of the Mybpc3 gene or its epigenetic environment that are prone to generate genetic mutations.

Very recently, a report in the Journal of the American Heart Association (Bellavia et al., 2013) provided evidence for the effects of ambient particulate-matter (PM) on blood pressure (BP). In humans, exposure to fine and coarse concentrated ambient particles (CAPs) induce blood hypomethylation of Alu, a transposable repeated element, and Toll-like receptor 4 (TLR4). Hypomethylation of both factors was found to be associated with increased systolic BP after exposure. This is of great interest since many epidemiological studies (O’Toole et al., 2008; Brooks, 2010) have reported a correlation between PM exposure, cardiovascular disease and death, and may therefore, represent a novel mechanism that modulates environmental effects on BP and indirectly cardiovascular disease and HF.

**HISTONE MODIFICATION IN HEART FAILURE**

**Histone acetylation**

Cardiac hypertrophy is the initial response to cardiac stress leading to adverse cardiac remodeling and eventually to HF. In order to elucidate the underlying mechanisms behind the development of cardiac hypertrophy, the role of histone acetylation/dereacetylation has been extensively studied. Gusterson et al. (2003) and Morita et al. (2010) demonstrated that overexpression of the transcriptional co-activators CREB binding protein (CRB) or p300, individually, could induce hypertrophic growth of cardiomyocytes depending on their histone HAT activity. Consequently, inhibition of these co-activators repressed phenylephrine (P)-induced hypertrophic cell growth (Gusterson et al., 2003). High expression and induced activity of HAT were observed in animals subjected to pressure overload, compared to sham operated animals, while heterozygous p300 transgenic animals revealed limited cardiac hypertrophy with preserved cardiac function when subjected to pressure overload (Morita et al., 2010). Intriguingly, another study showed that p300 transgenic animals develop HF at baseline, as indicated by high mortality, adverse remodeling and impaired cardiac function (Yanazume et al., 2003). Although these studies indicate that p300 is a crucial modulator of cardiac remodeling they do not specifically address the importance of its HAT activity in vivo. To assess this question, studies with transgenic animals carrying a mutant form of p300, with no HAT activity, were performed revealing a rescue of MI-induced pathological remodeling as well as preserved cardiac function compared to intact p300-carrying transgenic animals (Miyamoto et al., 2006). These responses to p300 modulation in vivo are, most likely, related to the fact that p300 can directly acetylate non-histone proteins such as hypertrophy-responsive transcriptional factors like MEF2 (Wei et al., 2008) and GATA-4 (Tanazume et al., 2003; Miyamoto et al., 2006).

The regulation of gene expression by HDACs seems to be more complex. HDACs are divided into four different classes (class-I, -IIa, -IIb and -IV) based on differences in their structure, enzymatic function, expression patterns and subcellular localization. Class I HDACs (HDAC1, 2, 3 and 8) are ubiquitously expressed in vivo, whereas class IIa HDACs (HDAC4, 5, 7, and 9) shuttle between the nucleus and the cytoplasm and are strictly expressed in muscle, heart and brain tissues (Haberland et al., 2003).
et al., 2009). A first demonstration of the relevant role of HDAC activity in cardiomyocytes derived from a study where myocardial differentiation of monkey ES cells was facilitated by TSA, an HDAC inhibitor (Hoseinikhan et al., 2007). Furthermore, differential chromatin scanning (DCS) is a technique used to genome-wide profile HDAC targets enabling the isolation of genomic fragments associated with histones and, therefore, carrying different acetylation marks (Kaneda et al., 2005). Such studies provide a basis for all following studies into the role of epigenetic modifications in cardiac disorders (Table 1). Interestingly, the two classes of HDACs show opposite roles in cardiac hypertrophy with class I HDACs being pro-hypertrophic and class IIa HDACs being anti-hypertrophic (Zhang et al., 2002; Antos et al., 2003; Chang et al., 2004). Induced expression of HDAC2 in cardiomyocytes mimics hypertrophic growth in an Akt-dependent manner. In vivo, class I HDAC2 overexpressing transgenic animals develop cardiac hypertrophy whereas HDAC2-null animals are protected from cardiac hypertrophic response after stimulation either by pressure overload or isoproterenol (ISO) administration (Trivedi et al., 2007). Similar to HATs, HDACs also interact with DNA binding proteins regulating their activity. For instance, class IIa HDACs (HDAC4, -5, -7 and -9) can directly interact with MEF2 leading to inhibition of MEF2 activity and subsequent reduced cardiac hypertrophy (Backs and Olson, 2006). On the other hand, when MEF2 is discharged of HDACs, it may become an available target for HATs binding which in turn leads to enhanced activity of MEF2 (Backs and Olson, 2006). Besides transcriptional factors, HATs and HDACs can also interact with sarcomeric proteins. PCAF, a HAT, class II HDAC4 co-localizes with cardiomyocyte sarcomeres in the Z-disc whereas class I HDAC3 localize mainly in the A-band (Gupta et al., 2008; Samant et al., 2011). In addition, inhibition of HDAC4 results in altered calcium sensitivity and therefore altered contractility. HDAC4 has an unique docking site for the binding of calcium/calmodulin-dependent kinase II (CaMKII), which is absent in other class IIa HDACs. Phosphorylation of HDAC4 by CaMKII promotes nuclear export and derepression of HDAC target genes, which, in cardiomyocytes, will lead to hypertrophic growth (Backs et al., 2006), indicating a central role for CaMKII-HDAC4 signaling pathways in the development of cardiac hypertrophy. From the HDAC class IIb, HDAC6 catalytic activity seems to be consistently increased in stressed myocardium and is activated by different extracellular stimuli in cultured cardiac myocytes (Lemon et al., 2011). Recently, Cao et al. (2011) showed that inhibition of HDAC6 by TSA (HDAC inhibitor) treatment limits its cardiac hypertrophy by suppressing autophagy. Further in vitro experiments, by selective downregulation of HDAC isoforms in cardiomyocytes, indicated HDAC1/2 as responsible for PE-induced autophagy (Cao et al., 2011). Autophagy is a self-degradative process during development and in response to nutrient stress, and can be altered under pathological conditions (Wang et al., 2013). Increasing evidence suggests more distinctive roles for HDACs besides only acting as histone deacetyltransferases.

### Histone methylation

The most widely studied histone methylations are lysine methylations: histone H3 lysine 4 (H3K4), H3K9, H3K27, H3K36, H3K79 and H4K20 (Martin and Zhang, 2005). There is limited information about the function of histone methylation in HF. It is known that differential methylation patterns for H3K4 and H3K9 occur in the vicinity of various gene clusters of failing human hearts (Kaneda et al., 2009). Because such sets of genes encode proteins that function in the same signal transduction pathways and H3K9 mark-profile seems to be less sensitive to disease status, this indicates differential H3K4 marking during the development of HF (Kaneda et al., 2009). Furthermore, in a Dahl salt-sensitive rat model of congestive heart failure (CHF), genome-wide histone methylation analysis revealed H3K4me3 and H3K9me3 as the most abundant histone methylation marks (Kaneda et al., 2009). Interestingly, mapping of H3K4me3 and H3K9me3 enriched regions in the genome of human CHF samples compared to controls revealed many HF-associated genes located in these regions (Kaneda et al., 2009). Moreover, histone methylation has been shown to mark not only protein coding genes but also non-coding RNA regions (Movassagh et al., 2011a). The genome wide mapping of H3K36me3 in end-stage failing human hearts allowed to identify 4 novel non-coding RNA regions, which have active transcription and might be involved in HF (Movassagh et al., 2011a). This differential profile of histone methylation marks found in both human and animal samples suggests a potential role for HMTs and HDMs in HF. Accordingly, JMJD2A, a histone trimethyl demethylase (Kooistra and Helin, 2012), is found to be upregulated in human HCM patients compared to control (Zhang et al., 2011). Moreover, transgenic mice with cardiac-specific overexpression of JMJD2A develop exaggerated cardiac hypertrophy compared to control mice following transverse aortic constriction (TAC) whereas smalda-null animals seem to be protected against TAC-induced cardiac stress (Zhang et al., 2011). All in all, these experiments indicate a potential modulator function for histone modification in HF.

### NON-CODING RNA IN HEART FAILURE

Post-transcriptional regulation of gene expression is mainly achieved by non-coding RNA molecules including miRNAs and, based on rather recent findings, long, non-coding RNAs (lncRNAs). Comparison of miRNA expression profiles in healthy and failing heart samples from humans or animal models revealed differential miRNA expression patterns indicating their potential involvement in the development and progression of HF. In this regard, miRNA microarray analysis of cardiac tissue from mouse models of cardiac hypertrophy and CHF detected five upregulated miRNAs (namely miR-24, miR-125b, miR-195, miR-199a and miR-214), which were further confirmed in idiopathic end stage failing human hearts (van Rooij et al., 2006). Furthermore, mice overexpressing miR-195 developed pathological remodeling, impaired cardiac function and subsequently HF (van Rooij et al., 2006). Besides distinct expression signatures of miRNAs in healthy and failing hearts, the differential miRNA expression profile among failing hearts is dependent on the underlying HF etiology (Ieda et al., 2007; Sucharov et al., 2008). Ieda et al. (2007) found 14 aortic stenosis-specific miRNAs while a set of other eight miRNAs were mainly expressed in a cardiomyopathic form of HF. In a similar study, different sets of miRNAs were found for...
Table 1 | Role of HDACs in heart disease.

| Class | Chromatin modifying factor | Modulation | Phenotype | Mechanism |
|-------|----------------------------|------------|-----------|-----------|
| Class I | HDAC2 | Germline deletion | Lethal at birth; Surviving adults are resistant to hypertrophy | Suppression of SRF and GATA4-dependent gene expression; Inhibition of hypertrophic Akt/GSK3β pathway |
| | Overexpression in myocardium | | Cardiac hypertrophy | Activation of hypertrophic Akt/GSK3β pathway |
| | Deletion in myocardium | | No cardiac phenotype | Redundancy with HDAC1 |
| | Deletion of HDAC1 and HDAC2 | Lethal at 2 weeks after birth: arrhythmias, dilated cardiomyopathy | | Interaction with REST repression of fetal genes involved in calcium handling and contractility |
| | Overexpression | | Cardiac hypertrophy without hypertrophy | Suppression of Cdk inhibitors; promotion of cardiomyocyte proliferation |
| | Deletion in myocardium | | Lethality at 3-4 months of age: cardiac hypertrophy, fibrosis, defects in fatty acid metabolism and lipid accumulation in the heart | Suppression of β3-ERα-dependent pathway |
| Class II | HDAC5/HDAC9 | Germline deletion | Enhanced hypertrophic response to cardiac stress; female hearts are protected from ischemia injury | Suppression of MEI2 and CAMTA2; suppression of MEI2-ERα-dependent pathway |
| Class III | SIRT1 | Overexpression in myocardium | Low-moderate expression of SIRT1 reduces cardiac hypertrophy; High levels induce cardiac hypertrophy and apoptosis | SIRT1 expression is activated by cardiac stress and regulates the response to stress in a dose-dependent manner |
| | Germline deletion | Cardiac hypertrophy and fibrosis at 12 months of age | | Inhibition of the proapoptotic activity of Bax |
| | Overexpression in myocardium | Resistant to stress induced cardiac hypertrophy | Activation of FOXO3α-dependent pathways; attenuation of the prohypertrophic MAPK/ERK and PI3K/Akt pathways. |
| | SIRT7 | Germline deletion | Cardiac fibrosis, hypertrophy and shortened lifespan | Deacetylation of p53, protection from stress-induced apoptosis |
idioopathic dilated and ischemic cardiomyopathy (Sucharov et al., 2008). Furthermore, the expression levels of miRNAs can vary as the disease progresses (Bagnall et al., 2012). This was shown in a double transgenic mouse model, harboring mutations in both the myosin heavy chain gene and the cardiac troponin I gene, resulting in severe HCM and premature mortality by age of 21 days. Global miRNA profiles in those mice, at age of 10 and 16 days, revealed stable downregulation of specific miRNAs such as miR-1 and miR-133, suggesting a functional role for these miRNAs throughout the progression to HF. Counterwise, miR-31 was upregulated at the end-stage of HF which points to a specific function for this miRNA during the final phase of the disease (Bagnall et al., 2012).

Another miRNA microarray profiling study has been carried out in human end-stage HF with or without left ventricular assist device (LVAD) compared to healthy subjects (Matovich et al., 2009). Twenty-eight miRNAs were differentially expressed in diseased hearts regardless of LVAD support and, interestingly, the expression levels of 20 of those miRNAs were either normalized or reversed in the CHF group after LVAD support suggesting an eventual value of such miRNAs as prognostic tools for end-stage CHF patients (Matovich et al., 2009). Recent data also emphasizes the variations between adult and child idiopathic dilated cardiomyopathy patients, regarding their miRNA expression profile (Stauffer et al., 2013). Naga Prasad et al. (2009) performed miRNA profiling studies at the time of diagnosis and at the time of event response at the drug response level (Szyf, 2004). This rapidly emerging new discipline, so-called pharmacoeigenomics, assesses the influence of epigenetic factors in the interindividual variation to drugs and in rats that were subjected to MI (Morimoto et al., 2008). However, the knowledge obtained from such studies combined with the knowledge on the role of epigenetic modifications is being applied to other complex forms of disease including HF.

The existent therapies for HF seem to be insufficient since HF remains the leading cause of death in the developed countries. Therefore there is an increasing necessity for finding novel therapeutic targets. Because the wide variability in an individual’s disease predisposition and response to treatment is only partially ascribed to heritable factors, epigenetical modifications diverging from DNA methylation to non-coding RNAs have gained much attention in several diseases, including HF (Feinberg, 2007; Mano, 2008). Therefore, epigenetic changes are currently being considered as therapeutic approaches in synergy with nucleotide variations at the drug response level (Szyf, 2004). A more recent study, besides showing that miRNA expression profiles differ between healthy and failing hearts, in consensus with previous findings, also demonstrated that failing adult hearts and fetal hearts display similar miRNA profiles supporting the paradigm of reactivation of a fetal gene program (Thum et al., 2007; Barry et al., 2008) at onset and/or during the development of HF.

On top of these profiling studies, a myriad of selected miRNAs were associated with cardiac disease-specific roles. miRNAs have also become a research focus on defining novel biomarkers of HF by characterizing miRNA patterns in easy accessible sources such as serum, plasma and even whole blood, and specific miRNA signatures have been identified as biomarkers of MI (Medex et al., 2011).

Interestingly, but not yet studied in the context of CVD, miRNA genes can be subject of DNA methylation with direct impact on the miRNA expression levels. Epigenetic regulation of miRNA genes was mainly showed, so far, for different types of cancer.
attenuate cardiac hypertrophic growth in transgenic mice with cardiac overexpression of the atypical homeodomain protein Hop, known to be able to inhibit certain cardiac gene expression by blocking serum response factor (SRF) transcription activity in a HDAC-dependent way (Kook et al., 2003). TSA is also able to attenuate pathological cardiac remodeling in other mouse models such as isoproterenol-, angiotensin II- and pressure overload-induced hypertrophy (Kook et al., 2003; Kee et al., 2006).

Considering that epigenetics regulates phenotypic variation in health and disease, it is conceivable that understanding and controlling the epigenome will prime great developments in the prevention and treatment of common diseases, including HF.

CONCLUSION

The dynamic aspects of epigenetics may not only provide more accurate evidences to the role of changing environmental factors but also offer a way to reactivate silenced genes. While accurate evidences to the role of changing environmental factors and accurate evidences to the role of changing environmental factors are required, dynamic aspects of epigenetics may not only provide more accurate evidences to the role of changing environmental factors but also offer a way to reactivate silenced genes.

REFERENCES

Ashen, C., Löhfelm, B., Thum, T., Gupta, S. K., Puhl, S. L., Schäfers, H. J., et al. (2012). Role of miR-21 in the pathogenesis of atrial fibrillation. Basic Res Cardiol. 107, 278. doi: 10.1007/s00395-012-0279-9

Anton, C. L., McKinsey, T. A., Dreyer, M., Hollenberg, L. M., Zhang, C. L., Schroeder, K., et al. (2003). Dose-dependent blockade of cardiac hypertrophy by histone deacetylase inhibitors. J. Biol. Chem. 278, 28930–28937. doi: 10.1074/jbc.M305152200

Baccarini, A., and Bollati, V. (2009). Epigenetics and environmental chemicals. Curr. Opin. Pulmonol. 15, 245–251. doi: 10.1097/MCP.0b013e32832f05cc

Bates, J., and Olson, E. N. (2010). Control of cardiac growth by histone acetylation/diacyetylation. Cell. 140, 95–104. doi: 10.1016/j.cell.2010.01.023

Bayles, R., Harikrishnan, K. N., Lamontagne, A., and Morris, R. E. (2008). CaM kinase II selectively signals to histone deacetylase 6 during cardiomyocyte hypertrophy. J. Clin. Invest. 118, 1853–1864. doi: 10.1172/JCI28743

Begall, R. D., Tsimoulis, T., Metzinger, B., Richter, W., and Sommerauer, C. (2012). Global microRNA profiling of the mouse ventricle during development of severe hypertrophic cardiomyopathy and heart failure. PLoS ONE 7:e47444. doi: 10.1371/journal.pone.0047444

Begar, R., Chen, D. A., Rada-Iglesian, A., Zhang, J., Xiong, Y., Holms, J., et al. (2010). CHRF2 cooperates with PAF1 to control multipoint neutral cell formation. Nature 463, 958–962. doi: 10.1038/nature08739

Balágh, F., Link, A., Lonas, I., Csatócsinca, M., Nagy, T., Balázs, C. R., et al. (2010). Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res. 70, 6609–6618. doi: 10.1158/0008-5472.CAN-10-0622

Barry, S. P., Duttenhofer, S. M., and Townsend, P. A. (2008). Dose-dependent blockade of cardiac hypertrophy by Histone deacetylase inhibitor Trichostatin A. J. Biol. Chem. 283, 20213–20219. doi: 10.1074/jbc.M802202200

Barra, B., Seib, S., Keränen, L., Lantto, J., Pinnola, E., Magan, K., et al. (2019). PARP inhibition delays transition of hypertensive cardiomyopathy to heart failure in spontaneously hypertensive rats. Cardiovasc. Res. 110, 501–516. doi: 10.1093/cvr/cvz044

Barra, B., Hariharan, K. N., Lamberti, E., Baker, E. K., Agrotis, A., Guo, L., et al. (2012). Epigenetic modification of the nonphosphoprotein transport gene is linked to ventricular arrhythmogenesis. Arterioscler. Thromb. Vasc. Biol. 32, 1910–1916. doi: 10.1161/ATVBAHA.111.244493

Bekris, A. K., Sanoss, S. E., Terentiev, Y., Ho, H. T., Nishijima, Y., Martin, M. M., et al. (2011). MicroRNA-1 and –133 increase arrhythmogenicity in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS ONE 6:e18234. doi: 10.1371/journal.pone.0018234

Bellevat, A., Uich, B., Speck, M., Peer, M., Breit, J. A., Alberti, B., et al. (2013). DNA hypomethylation, ambient particulate matter, and increased blood pressure: findings from controlled human exposure experiments. J. Am. Heart Assoc. 2, e001212

Bhutani, N., Burt, D. M., and Blau, H. M. (2011). DNA demethylation dynamics. Gen. 46, 866–872. doi: 10.1016/j.cell.2011.08.042

Bird, A. (2007). Perspectives of epigenetics. Nature 447, 398–399. doi: 10.1038/nature05915

Blanco, R. A., Austin, H., Vest, R. N. III, Valdicer, R., Li, W., Lasagabue, B., et al. (2012). Angiotensin receptor type 1 single nucleotide polymorphism 1166A/C is associated with malignant arrhythmias and altered circulating miR-155 levels in patients with chronic heart failure. J. Card. Fail. 18, 717–723. doi: 10.1016/j.cardfail.2012.06.531

Bodi, N., Baiden, J. M., Ballard, D. J., and Summers, K. M. (2011). Molecular genetics of long QT syndrome: MiGE Mutations. Circ. Arrhythm. Electrophysiol. 4, 1–8. doi: 10.1161/CIRCEP.110.950074

Brouschue, D., Olah, J., Tchkılov, C., Balasubramanyam, A., George, P., Baker, E. K., et al. (2009). Hyperglycemia induces a dynamic coregulatory network and deoxymethase enzymes associated with gene-activating epigenetic marks that coexist on the lyssna tail. Diabetes 58, 1220–1238. doi: 10.2337/db08-1619

Broadway, H. M., Poles, J. F., Lokhorst, S., Geval, A., Ongen, H., Green, F., et al. (2018). Susceptibility to coronary artery disease and diabetes is encoded by a novel, highly linked SNP in the ANSEIL locus on chromosome 1p. J Hum. Genet. 67, 901–914. doi: 10.1038/hmg.2018.532

Brook, D. R., Raggi, P., Sinaiko, A. D., and Raggi, P., et al. (2011). Role for MicroRNA-21 in atrial profibrillatory fibrillatory remodeling associated with experimental postinfarction heart failure. Circ. Arterioscler. Electrophysiol 5, 1027–1035. doi: 10.1161/CIRC. A10273214

Burgos, D. J. (2012). Cancer genomics: Epigenetic modification at the gene level. Nat. Rev. Genet. 13, 148–149.

Callin, T. E., Pandy, K., Seek, H. Y., Tang, B. H., Tani, S., Zhao, X. S., et al. (2009). MicroRNA-20a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest. 119, 2772–2786. doi: 10.1172/JCI36354

Cao, D. J., Wang, Z. V., Batiprolu, P. K., Jiang, N., Morales, C. B., Keng, Y., et al. (2011). Histone demethylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc. Natl. Acad. Sci. U.S.A. 108, 4125–4128. doi: 10.1073/pnas.1013801108

Cardin, S., Gunath, E., Luo, X., Nandi, P. L., Le, K., Shi, Y., et al. (2012). Role for MicroRNA-21 in atrial profibrillatory fibrillatory remodeling associated with experimental postinfarction heart failure. Circ. Arterioscler. Electrophysiol 5, 1027–1035. doi: 10.1161/CIRC. A10273214

Duygu et al. (Epi)genetics of heart failure

"fgene-04-00219" — 2013/10/30 — 11:38 — page 11 — #11

www.frontierin.org

October 2013 | Volume 4 | Article 2 | 11
Duygu et al. (Epi)genetics of heart failure

Cheung, P. and Lau, P. (2005).

Colussi, C., Berni, R., Rosati, J., Clapier, C. R., and Cairns, B. R. (2004).

Creemers, E. E., Wilde, A. A., and Pinto, L. S., Park, D. S., Rotllan, D., Danielson, L. S., and Mahadevan, L. C. (2006).

Elliott, P. and McKenna, W. J. (2004).

Frontiers in Genetics 10.1128/MCB.24.19.8467-8476.2004. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004

Frontiers in Genetics 10.1128/MCB.24.19.8467-8476.2004. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.

Frontiers in Genetics 2013. Cardiovascular dysregulation and PCAF bind to cardiac sarcomere and play a critical role in cardiac hypertrophy. J. Biol. Chem. 24, 8467–8476. doi:10.1128/MCB.24.19.8467-8476.2004.
transcriptional repression mediated by the atrial hemoglobin protein Taf1p. J Clin Invest 112, 843–871.

Kominama, A., and Griffiths-Jones, S. (2001). miRNA: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 29, D132–D137. doi: 10.1093/nar/gk1277

Lachner, M., and Jenuwein, T. (2002). The many faces of histone lysine methylation. Curr. Opin. Cell Biol. 14, 288–298. doi: 10.1016/S0955-2863(02)00315-6

Land, P. W. (2003). The power and the promise of DNA methylation marks. Nat. Rev. Cancer 3, 253–266. doi: 10.1038/nrc988

Lee, K. C., Feinbaum, R. L., and Ambros, V. (1999). The C. elegans heterochromatin gene lin-14 encodes small RNAs with antisense complementarity to lin-14. Cell 97, 843–854. doi: 10.1016/S0092-8674(99)00282-Y

Lee, Y. V., Aoki, C., Han, J., Hsu, H., Kim, J., Yim, J., et al. (2003). The nuclear RNAIII Drosha initiates microRNA processing. Nature 425, 413–419. doi: 10.1038/nature01975

Lee, Y. M., Kim, M., Han, Y., Jeon, K. H., Lee, S., Baek, S. H., et al. (2004). MicroRNA genes are trancribed by RNA polymerase II. EMBO J. 23, 4152–4160. doi: 10.1038/nrg1307

Li, E. (2002). Chromatin modification by the atypical homeodomain protein Cbx1. Nat. Rev. Mol. Cell Biol. 3, 269–276. doi: 10.1038/nrm887

Ling, C., and Groop, L. (2009). Epigenetics: deciphering how environmental factors may modify autoimmune type 1 diabetes. Nat. Rev. Genet. 10, 144–155. doi: 10.1038/nrg2552

Mancini-DiNardo, D., Steele, S. J., Meurs, K. M., and Kuan, M. (2011). Novel therapeutic approaches for acute lymphoblastic leukemia. Hum. Oncol. Crit. Care North Am. 25, 1393–1397. doi: 10.1016/j.hincc.2011.09.019

Li, M., Liu, M. D., Petkova, N. B., Lu, M. M., Wang, T., Yuan, L. J., et al. (2008). Histone-deacetylase inhibition reverses cardiac atrophy and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol. 45, 715–725. doi: 10.1016/j.yjmcc.2008.08.015

Lopes, L. R., Elliott, P. M. (2011). Genetics of heart failure: A short review. Front. Physiol. Acta doi: 10.3389/fphys.2011.01212 [Epub ahead of print].

Li, Y., Zhang, Y., Wang, N., Pan, Z., Yu, Z., Feng, Z., et al. (2010). MicroRNA-326 contributes to adverse electrical remodeling in atrial fibrrillation. Circulation 122, 2378–2387. doi: 10.1161/CIRCULAT EION.109.899124

L Intelligent, A., and Lowe, S. W. (2012). The microRNA genome of cancer. Nat Rev. 426, 347–355. doi: 10.1038/nature10808

Macfarlane, A. J., Streim, A., and Scott, F. W. (2009). Epigenetic deciphering how environmental factors may modify autoimmune type 1 diabetes. Mamm. Genome 20, 628–632. doi: 10.1007/s00335-009-9213-6

Marchionni, P., Wullschleger, J., and Tjian, R. (2003). A differentially methylated region within the gene Kcnq1 regulates tie-1 locus regulates tie-1 function in vivo. Blood 115, 133–139. doi: 10.1182/blood-2009-04-241180

Li, Y. G., Zhang, P. P., Jiao, K. L., and Zuo, Y. Z. (2009). Knockdown of microRNA-1 by lentivirus mediated siRNA expression vector decreases the cardiomyogenic effect of skeletal myoblast transplantation in rat with myocardial infarction. Microvasc. Res. 78, 393–404. doi: 10.1016/j.mvr.2009.06.011

Lichtert, B., Tauchert, J. K., Noth I, Both, J., Wallr, R., MiethkeI, F., Adamson, S. L., et al. (2004). Batn is essential for Rb chromatin remodelling complex in heart development. Nat. Genet. 36, 107–112. doi: 10.1038/ng1037

Ling, C., and Groop, L. (2009). Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 58, 2178–2179. doi:10.2337/db08-1010

Li, C. (2013). Novel therapeuic approaches for acute lymphoblastic leukemia. Hum. Oncol. Crit. Care North Am. 25, 1393–1397. doi: 10.1016/j.hincc.2011.09.019

Li, E., Leven, M. D., Petkova, N. B., Lu, M. M., Wang, T., Yuan, L. J., et al. (2008). Histone-deacetylase inhibition reverses cardiac atrophy and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol. 45, 715–725. doi: 10.1016/j.yjmcc.2008.08.015

Lopes, L. R., and Elliott, P. M. (2011). Genetics of heart failure: A short review. Front. Physiol. Acta doi: 10.3389/fphys.2011.01212 [Epub ahead of print].

Li, Y., Zhang, Y., Wang, N., Pan, Z., Yu, Z., Feng, Z., et al. (2010). MicroRNA-326 contributes to adverse electrical remodeling in atrial fibrrillation. Circulation 122, 2378–2387. doi: 10.1161/CIRCULAT EION.109.899124

L Intelligent, A., and Lowe, S. W. (2012). The microRNA genome of cancer. Nat Rev. 426, 347–355. doi: 10.1038/nature10808

Macfarlane, A. J., Streim, A., and Scott, F. W. (2009). Epigenetic deciphering how environmental factors may modify autoimmune type 1 diabetes. Mamm. Genome 20, 628–632. doi: 10.1007/s00335-009-9213-6

Marchionni, P., Wullschleger, J., and Tjian, R. (2003). A differentially methylated region within the gene Kcnq1 regulates tie-1 locus regulates tie-1 function in vivo. Blood 115, 133–139. doi: 10.1182/blood-2009-04-241180

Li, Y. G., Zhang, P. P., Jiao, K. L., and Zuo, Y. Z. (2009). Knockdown of microRNA-1 by lentivirus mediated siRNA expression vector decreases the cardiomyogenic effect of skeletal myoblast transplantation in rat with myocardial infarction. Microvasc. Res. 78, 393–404. doi: 10.1016/j.mvr.2009.06.011

Lichtert, B., Tauchert, J. K., Noth I, Both, J., Wallr, R., MiethkeI, F., Adamson, S. L., et al. (2004). Batn is essential for Rb chromatin remodelling complex in heart development. Nat. Genet. 36, 107–112. doi: 10.1038/ng1037

Ling, C., and Groop, L. (2009). Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 58, 2178–2179. doi:10.2337/db08-1010

Li, C. (2013). Novel therapeuic approaches for acute lymphoblastic leukemia. Hum. Oncol. Crit. Care North Am. 25, 1393–1397. doi: 10.1016/j.hincc.2011.09.019

Li, E., Leven, M. D., Petkova, N. B., Lu, M. M., Wang, T., Yuan, L. J., et al. (2008). Histone-deacetylase inhibition reverses cardiac atrophy and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol. 45, 715–725. doi: 10.1016/j.yjmcc.2008.08.015

Lopes, L. R., and Elliott, P. M. (2011). Genetics of heart failure: A short review. Front. Physiol. Acta doi: 10.3389/fphys.2011.01212 [Epub ahead of print].

Li, Y., Zhang, Y., Wang, N., Pan, Z., Yu, Z., Feng, Z., et al. (2010). MicroRNA-326 contributes to adverse electrical remodeling in atrial fibrrillation. Circulation 122, 2378–2387. doi: 10.1161/CIRCULAT EION.109.899124
Novartis Found. Symp. 274, 3–12. doi: 10.1002/0470925392.3

Oshiro, J. M., and Smith, C. E. (2010). Epigenetics and cardiovascular disease. Nat. Rev. Cardiol. 7, 510–519. doi:10.1038/nrcardio.2010.104

O’Toole, T. E., Connell, D. J., and Bhattacharjee, A. (2008). Environmental risk factors for heart disease. Rev. Environ. Health 23, 167–202. doi:10.1016/S0360-2011(08)15317-7

Palki, A., Tsykh, A., Kant, K., Dene, P., Szabó, E., Zsámadó, Z., et al. (2006). PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase 3β pathway. J. Mol. Cell Cardiol. 41, 149–158. doi:10.1016/j.yjmcc.2006.04.027

Pannuti, A., and Jezzini, B. (1996). DNA hypomethylation can activate Xist expression and silence X-linked genes. Genes Dev. 10, 1991–2002. doi:10.1101/gad.10.11.1991

Pili, J. B., Gupta, M., Rajamohan, S. B., Lang, B., Raman, J., and Gupta, M. P. (2008). Poly(ADP-ribose) polymerase-1 deficient mice are protected from angiotensin II-induced cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 291, H2450–H2515.

Pili, J. B., Ishibani, A., Imai, S., and Gupta, M. P. (2009a). Poly(ADP-ribose) polymerase-1 deficient mice are protected from myocardial cell death during heart failure mediated by Na+/Ca2+ depletion and reduced Ser/Thr phosphatase activity. J. Biol. Chem. 284, 4521–4523.

Pili, J. B., Russell, H. M., Raman, J., Ishaev, S., Gupta, and Gupta, M. P. (2009b). Increased expression of poly(ADP-ribose) polymerase-1 confers resistance to myocardial cell death during heart failure. Am. J. Physiol. Heart Circ. Physiol. 288, H4860–H4866.

Quint, D., and Olsen, E. N. (2013). miRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. J. Mol. Med. 11, 11–18. doi:10.1007/JM214

Robb, G. B., Carson, A. B., Tai, S. C., Fish, J. E., Singh, S., Sotada, T., et al. (2007). Post-transcriptional regulation of the endothelial nitric oxide synthase by an overlapping antisense miRNA transcript. J. Biol. Chem. 282, 37989–37996. doi:10.1074/jbc.M701217200

Rosales, K., Chen, X., Friend, R., and Willis, M. S. (2009). Familial hypertrophic cardiomyopathy: basic concepts and future molecular diagnostic clues. Biochem. Biophys. Acta 1787, 755–763.

doi:10.1016/j.clinbiochem.2009.03.020

Saccone, S., and Nanot, G. (2002). Dynamic changes in histone H3 lys 9 methylation occurring at tightly regulated inflammatory genes. Genes Dev. 16, 2219–2224. doi:10.1101/gad.225202

Sato, Y., Liang, G., Egger, G., Friedman, J. M., Chuang, J. C., Couto, A. G., et al. (2006). Specific activation of microRNAs 127 with downregulation of the proto-oncogene BCL6 by chromatine remodeling drugs on human cancer cells. Cancer Cell 9, 455–465. doi:10.1016/j.ccc.2006.04.020

Samura, S., Crouse Jr., D. S., Sundararajan, N. R., Pillai, V. R., Tan, M., Zhao, Y., et al. (2011). HDAC3-dependent reversible lysine acetylation of cardiac myosin heavy chain isoforms modulates their enzymatic and motor activity. J. Biol. Chem. 286, 5567–5577. doi:10.1074/jbc.M110.116605

Sauter, S., Berg, P., and Brüggen, D. L. (2006). A genome-wide analysis of Cpg dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc. Natl. Acad. Sci. U.S.A. 103, 1412–1417. doi:10.1073/pnas.0510013103

Sayad, D., and Abdellatif, M. (2011). MicroRNAs in development and disease. Physiol. Rev. 91, 827–887. doi:10.1152/physrev.00010.2010

Sawin, S. E., Szabo, G., Bährle, S., Stumpf, N., Sonnenberg, K., Stuhl, E. F., Pachter, P., et al. (2002). Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ. Res. 90, 106–116. doi:10.1161/01.RES.102.10.106

Sfyroeras, M. (2004). Toward a discipline of pharmacogenomics. Curr. Pharmacogenomics 2, 357–357. doi:10.17177/cpg.2004.357

Shan, H., Zhang, Y., Lu, Y., Zhang, Y., Pan, Z., Cai, B., et al. (2009). Down-regulation of micro miR-133 and miR-21 promotes p300-specific histone acetyltransferase activity. J. Biol. Chem. 284, 209–215.

Shain, K. H., Patel, S. R., Day, S. M., Noureldin, A., and Willis, M. S. (2009). Familial hypertrophic cardiomyopathy in autosomal recessive dilated cardiomyopathy. J. Mol. Med. 87, 1991–2002. doi:10.1002/cncr.246584

Shtilman, E., and Diederichs, S. (2009). DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 9, 465–466. doi:10.1038/nrg2541

Siu, S., Bahní, S., Šumpík, N., Sonnenberg, K., Stuhl, E. F., Pachter, P., et al. (2002). Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ. Res. 90, 106–116. doi:10.1161/01.RES.102.10.106

Szyf, M. (2004). Toward a discipline of pharmacogenomics. Curr. Pharmacogenomics 2, 357–357. doi:10.17177/cpg.2004.357

Stein, A. B., Jones, T. A., Herron, T., et al. (2011). Loss of HDAC3-dependent myocardial hypertrophy and autophagy: metabolic profit and loss. J. Mol. Med. 89, 764–771. doi:10.1007/s00109-010-0893-9

Wang, Y., Luo, Y., Yin, Z., Zhang, W., Xu, X., Sun, X., Yamamoto, M., Chovanalekouplakos, K., et al. (2007). BR浑身 is a nuclear Nrf2-signaling component required for the establishment of left-right asymmetry. Proc. Natl. Acad. Sci. U.S.A. 104, 8464–8469. doi:10.1073/pnas.0701611104

Wieser, K., Gomperts, S. B., Jakuma, J. W., Quan, P. H., and van den Elshout, E. P. (2010). Epigenetics in atherosclerosis and inflammation. J. Cell Mol. Med. 14, 1225–1240. doi:10.1111/j.1582-4934.2010.01022.x

Witten, J., Jung, S., Keller, S., Georgy, R. S., and Schirdel, S. G. (2008). Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Genet. 41, 228–234. doi:10.1038/ng1909-228

Xiao, C., Chen, Y., Yu, Z., Zou, X., Liu, Z., Liu, Z., et al. (2005). Poly(ADP-Ribose)polymerase promotes cardiac remodeling, contractile failure, and translocation of apoplosis-inhibiting protein Bcl-2 to the mitochondrial outer membrane of aortic smooth muscle cells. J. Pharmacol. Exp. Ther. 312, 891–898. doi:10.1124/jpet.105.087704

"fgen-e04-00219" — 2013/10/30 — 11:38 — page 14 — #14

Epigenetics of heart failure

Frontiers in Genetics | Epigenomics and Epigenetics

October 2013 | Volume 4 | Article 219 | 14
Xiao, J., Liang, D., Zhang, Y., Liu, Y., Zhang, H., Liu, Y., et al. (2011). MicroRNA expression signature in atrial fibrillation with mitral stenosis. Physiol. Genomics 45, 655–666. doi: 10.1152/physiogenomics.00139.2010

Yan, M. S., Matsuki, C. C., and Matsuzaki, P. A. (2010). Epigenetics of the vascular endothelium. J. Appl. Physiol. 108, 936–928. doi: 10.1152/japplphysiol.00350.2010

Yamamoto, T., Haeg cad, K., Morigome, T., Kanamori, T., Wada, H., Matsunoto, A., et al. (2003). Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol. Cell. Biol. 23, 3593–3606. doi: 10.1128/MCB.23.10.3593-3606.2003

Yang, B., Lin, H., Xiao, J., Liu, Y., Xiao, X., Li, B., et al. (2007). The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat. Med. 13, 486–491. doi: 10.1038/nm1569

Yang, X. J., and Sena, E. (2008). The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 9, 206–218. doi: 10.1038/nrm2346

Zheng, C. L., McKinney, T. A., Chang, S., Amos, C. L., Hill, J. A., and Olson, E. N. (2002). Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479–488. doi: 10.1016/S0092-8674(02)00861-9

Zheng, Q. J., Chen, H. Z., Wang, L., Liu, D. P., Hill, J. A., and Liu, Z. P. (2011). The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. J. Clin. Invest. 121, 2447–2456. doi: 10.1172/JCI48277

Zhao, Y., Ransome, J. F., Li, A., Velayudham, Y., von Drohle, M., Math, A. N., et al. (2007). Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129, 303–317. doi: 10.1016/j.cell.2007.01.050

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 25 September 2013; accepted: 08 October 2013; published online: 20 October 2013.

Citation: Duygu B, Poels EM and da Costa Martins PA (2013) Genetics and epigenetics of arrhythmia and heart failure. Front. Genet. 4:219. doi: 10.3389/fgene.2013.00219

This article was submitted to Epigenomics and Epigenetics, a section of the journal Frontiers in Genetics.

Copyright © 2013 Duygu, Poels and da Costa Martins. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.